A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease
Latest Information Update: 26 Aug 2024
At a glance
- Drugs ION 859 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms REASON
- Sponsors Biogen
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2023 Planned End Date changed from 2 Dec 2023 to 26 Dec 2024.